Use of hemoglobin derivatives for determining plasma and/or blood volume

US6416736B1 · kind B1 · utility

Assignees

• Fresenius Kabi Deutschland GmbH · DE
• R & D Center · DE

Inventors

• Frank Bepperling · Bad Nauheim, DE
• Wolfram Eichner · Rockenberg, DE
• Klaus Sommermeyer · Rosbach, DE
• Jens Opitz · Frankfurt, DE

Key dates

• Filing date: Jul 11, 2000
• Grant date: Jul 9, 2002
• Expiry date: Jul 11, 2020

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P7/00
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The invention concerns the use of hemoglobin derivatives for determining plasma and/or blood volume, wherein the hemoglobin derivatives are stable chromoproteins with a molecular weight of at least 64 kDa. The use can encompass the treatment of a patient wherein(a) a defined quantity of hemoglobin derivative is applied to a patient,(b) the mixing of hemoglobin derivative with the blood of the patient is awaited,(b) at least one sample is taken from the patient,(c) the content of the hemoglobin derivative and/or the content of the hemoglobin derivative bound ligand in the sample is determined and(d) the plasma and/or blood volume ascertained therefrom.The invention also concerns preparations for determining plasma and/or blood volume which contain hemoglobin derivatives and are characterized in that the hemoglobin derivatives are stable chromoproteins with a molecular weight of at least 64 kDa which carry at least in part carbon monoxide as ligand, as well as processes for their manufacture.